By Ben Hirschler LONDON (Reuters) – A British vote to leave the European Union would threaten some prescription medicines with regulatory limbo, posing a legal headache for drugmakers, according to lawyers and industry officials. The highly regulated pharmaceutical sector has more at stake than most from a so-called Brexit, prompting top manufacturers GlaxoSmithKline and AstraZeneca , both of which oppose exit, to draw up detailed contingency plans. Smaller UK biotech companies, represented by the BioIndustry Association, also fear a decision to leave would disrupt the market and could affect patient access to medicines.
Read the original:
Illicit drugs? How Brexit risks legal limbo for medicines